Research Analysts Issue Forecasts for Amgen Q4 Earnings

Amgen Inc. (NASDAQ:AMGN) – William Blair lowered their Q4 2025 earnings estimates for shares of Amgen in a note issued to investors on Wednesday, November 5th. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings per share of $4.61 for the quarter, down from their previous estimate of $5.60. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen’s Q1 2026 earnings at $5.37 EPS, Q2 2026 earnings at $5.89 EPS, Q3 2026 earnings at $5.57 EPS, Q4 2026 earnings at $5.06 EPS, FY2027 earnings at $22.61 EPS and FY2028 earnings at $22.78 EPS.

Several other equities research analysts also recently issued reports on AMGN. Citigroup raised their price target on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a report on Wednesday. UBS Group reduced their price target on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. The Goldman Sachs Group reduced their price objective on Amgen from $405.00 to $400.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Guggenheim upped their price target on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $308.83.

Amgen Stock Performance

Amgen stock traded up $2.52 during midday trading on Friday, reaching $318.11. 276,829 shares of the company’s stock were exchanged, compared to its average volume of 2,726,369. Amgen has a 52 week low of $253.30 and a 52 week high of $335.88. The firm has a market cap of $171.26 billion, a price-to-earnings ratio of 25.97, a P/E/G ratio of 2.61 and a beta of 0.45. The stock’s 50-day simple moving average is $289.29 and its 200 day simple moving average is $288.18. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be issued a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 3.0%. Amgen’s dividend payout ratio is presently 73.57%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently modified their holdings of AMGN. TAGStone Capital Inc. raised its holdings in shares of Amgen by 0.8% in the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares during the last quarter. Wealth Quarterback LLC grew its position in Amgen by 1.6% during the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after buying an additional 34 shares in the last quarter. DDFG Inc grew its position in Amgen by 1.1% in the third quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock worth $850,000 after acquiring an additional 34 shares in the last quarter. Fairvoy Private Wealth LLC grew its position in Amgen by 1.1% during the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock valued at $885,000 after acquiring an additional 35 shares during the last quarter. Finally, Nicholson Wealth Management Group LLC increased its holdings in shares of Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock worth $1,652,000 after buying an additional 35 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.